ERBB3 and breast carcinoma: High levels of circulating EVs containing drug targets and their modifiers (HER-2-EVs may act as both antagonist and indicators of reduced efficacy of trastuzumab; the content of HER-3 in breast cancer EVs may suggest resistance to HER-2 inhibitors)